We have 2 components of research at present: i) Two grants received for a COVID-19 product being researched through the University of Manitoba ii) Grant applications currently being reviewed for studying the addition of a novel protein to insulin formulations to prevent/minimize or delay the onset of secondary diseases normally associated with Type 1 diabetes (T1D) (Cancer, Alzheimer's disease, Cardiovascular disease, nephropathy, and related kidney issues, NAFLD, circulatory issues, skin ulcers, amputations, etc). This protein has an extremely complex signalosome that has been deduced for the mode of action. If grant funding is received, Intellectual Property (IP) will be generated around the data and leveraged to help raise Angel Investor/VC funding. We have partnered with a global AI company (more information later) to help develop key biomarkers and indications to pursue during clinical trials to help further solidify generated IP and potentially pursue novel indications. Many other sub-projects will be described as they move closer towards reality.